focus -WSS

focus

author：entertainment 2025-09-30 01:13:56 - browse：8

PHILADELPHIA — Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster drugs Ozempic and Wegovy, now also wants to be a major player in heart disease.

The landmark Select trial presented over the weekend — which showed Wegovy significantly cut the risk of heart complications — is just one of many efforts by the Danish drugmaker to expand into the cardiovascular space. It’s also developing several treatments specific to heart disease and is acquiring a medication for high blood pressure.

“We have a clear vision of being an established cardiovascular company, just as we see ourselves as leaders in diabetes and obesity,” Martin Lange, Novo’s executive vice president of development, said in an interview here at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： 2024 GOP presidential candidates spar over abortion in debate

explore

WSS

AMAs digital advisors table RPM coding reform proposal, again

2024 GOP presidential candidates spar over abortion in debate

How a symptom of dementia informs our understanding of creativity

Congress must protect the remaining independent doctors

Appeals court upholds limits to abortion pill

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

focus

focus

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

Report cites 'urgent' need to recruit more diverse clinical trial participants

BioMarin wins approval for gene therapy to treat hemophilia A

Winners, losers from Medicare’s list of drugs subject to price talks

Hepatitis C has a cure — but many Americans still lack access to it

Psilocybin's anti

23andMe had bad news about my health. I wish a person had delivered it

AstraZeneca bets AAV gene therapy will still deliver the goods

After affirmative action ruling, medical educators look to 'holistic review'

How Long Island became the ‘eugenics capital of the world’

leisure time

Why don't Americans have at

Winners, losers from Medicare’s list of drugs subject to price talks

In science, is the line between industry and academia shifting?

Medicare explains how it will choose drugs for negotiation

Congress must protect the remaining independent doctors

Australia’s approach to dialysis celebrates life

explore

focus

focus

focus